Pages that link to "Q61788033"
Jump to navigation
Jump to search
The following pages link to Single administration of low dose cyclophosphamide augments the antitumor effect of dendritic cell vaccine (Q61788033):
Displaying 50 items.
- Chemotherapeutic agents in noncytotoxic concentrations increase antigen presentation by dendritic cells via an IL-12-dependent mechanism (Q28384980) (← links)
- Randomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccine (Q30425914) (← links)
- Immunological factors relating to the antitumor effect of temozolomide chemoimmunotherapy in a murine glioma model (Q33613430) (← links)
- Cyclophosphamide induces bone marrow to yield higher numbers of precursor dendritic cells in vitro capable of functional antigen presentation to T cells in vivo (Q33653210) (← links)
- Low-dose cyclophosphamide synergizes with dendritic cell-based immunotherapy in antitumor activity (Q33871059) (← links)
- Enhancement of antitumor effect using dendritic cells activated with natural killer cells in the presence of Toll-like receptor agonist (Q33942806) (← links)
- Pattern response of dendritic cells in the tumor microenvironment and breast cancer (Q34023724) (← links)
- Enhanced T-cell-independent antitumor effect of cyclophosphamide combined with anti-CD40 mAb and CpG in mice (Q34541830) (← links)
- Dendritic cell recovery post-lymphodepletion: a potential mechanism for anti-cancer adoptive T cell therapy and vaccination (Q34759603) (← links)
- α-Tocopheryloxyacetic acid: a novel chemotherapeutic that stimulates the antitumor immune response (Q35029521) (← links)
- Proposed mechanisms of action for prostate cancer vaccines. (Q35174754) (← links)
- Immunotherapy using dendritic cells against multiple myeloma: how to improve? (Q35852574) (← links)
- Cellular immunotherapy using dendritic cells against multiple myeloma (Q35865581) (← links)
- The tumor microenvironment expression of p-STAT3 influences the efficacy of cyclophosphamide with WP1066 in murine melanoma models. (Q35871559) (← links)
- The tipping point for combination therapy: cancer vaccines with radiation, chemotherapy, or targeted small molecule inhibitors (Q35975387) (← links)
- Pancreatic adenocarcinoma upregulated factor serves as adjuvant by activating dendritic cells through stimulation of TLR4 (Q36413897) (← links)
- Treatment with cyclophosphamide supported by various dendritic cell-based vaccines induces diversification in CD4⁺ T cell response against MC38 colon carcinoma (Q36498103) (← links)
- CpG-1826 immunotherapy potentiates chemotherapeutic and anti-tumor immune responses to metronomic cyclophosphamide in a preclinical glioma model (Q36600960) (← links)
- Harnessing dendritic cells for tumor antigen presentation (Q37132747) (← links)
- Regulatory T cells and treatment of cancer (Q37174953) (← links)
- Combination of active specific immunotherapy or adoptive antibody or lymphocyte immunotherapy with chemotherapy in the treatment of cancer (Q37299843) (← links)
- Use of anti-cancer drugs, mitocans, to enhance the immune responses against tumors. (Q37308070) (← links)
- Potential survival benefit of anti-apoptosis protein: survivin-derived peptide vaccine with and without interferon alpha therapy for patients with advanced or recurrent urothelial cancer--results from phase I clinical trials (Q37393594) (← links)
- Enhancement of antitumor immunity by low-dose total body irradiationis associated with selectively decreasing the proportion and number of T regulatory cells (Q37727283) (← links)
- Cyclic adenosine monophosphate involvement in low-dose cyclophosphamide-reversed immune evasion in a mouse lymphoma model (Q37727843) (← links)
- Breaking tolerance in a mouse model of multiple myeloma by chemoimmunotherapy. (Q37732959) (← links)
- Directing dendritic cell immunotherapy towards successful cancer treatment (Q37754014) (← links)
- Human FOXP3 and cancer (Q37760416) (← links)
- How tumors might withstand γδ T-cell attack. (Q37872644) (← links)
- The tumor microenvironment: a pitch for multiple players. (Q38101567) (← links)
- Immune recovery after cyclophosphamide treatment in multiple myeloma: implication for maintenance immunotherapy. (Q38729516) (← links)
- Adapting conventional cancer treatment for immunotherapy (Q38748185) (← links)
- Adjuvant Autologous Melanoma Vaccine for Macroscopic Stage III Disease: Survival, Biomarkers, and Improved Response to CTLA-4 Blockade. (Q38764852) (← links)
- Low-dose chemotherapeutic agents regulate small Rho GTPase activity in dendritic cells (Q39000198) (← links)
- Enhanced therapeutic effect of B cell-depleting anti-CD20 antibodies upon combination with in-situ dendritic cell vaccination in advanced lymphoma (Q39250390) (← links)
- Cyclophosphamide Potentiates the Antitumor Effect of Immunization with Injection of Immature Dendritic Cells into Irradiated Tumor (Q39594003) (← links)
- Chemomodulation of human dendritic cell function by antineoplastic agents in low noncytotoxic concentrations (Q39826691) (← links)
- Anti-inflammatory cytokines: important immunoregulatory factors contributing to chemotherapy-induced gastrointestinal mucositis. (Q42113023) (← links)
- Combination immunotherapy for tumors via sequential intratumoral injections of oncolytic herpes simplex virus 1 and immature dendritic cells (Q42280087) (← links)
- Dendritic cell vaccine in addition to FOLFIRI regimen improve antitumor effects through the inhibition of immunosuppressive cells in murine colorectal cancer model (Q42872791) (← links)
- Cell-based Hyper-interleukin 6 or Hyper-interleukin 11 secreting vaccines combined with low dose cyclophosphamide in an orthotopic murine prostate cancer model (Q43190686) (← links)
- T cell modulation by cyclophosphamide for tumour therapy. (Q49822317) (← links)
- Interleukin-15 enhances T-cell responses by stimulation with dendritic cells (Q51012673) (← links)
- A novel function of API5 (apoptosis inhibitor 5), TLR4-dependent activation of antigen presenting cells (Q57133698) (← links)
- Combination Strategies to Optimize Efficacy of Dendritic Cell-Based Immunotherapy (Q60046432) (← links)
- Variable effects of cyclophosphamide in rodent models of experimental allergic encephalomyelitis (Q60981640) (← links)
- Surgically Unresectable Regional Melanoma Metastases in a Patient With Renal Failure and Peripheral Vascular Disease: Are There Safe and Potentially Effective Treatments? (Q84979126) (← links)
- Antitumor immunity of low-dose cyclophosphamide: changes in T cells and cytokines TGF-beta and IL-10 in mice with colon-cancer liver metastasis (Q89910802) (← links)
- Immune microenvironment modulation unmasks therapeutic benefit of radiotherapy and checkpoint inhibition (Q92599670) (← links)
- Harnessing T-cell activity against prostate cancer: A therapeutic microparticulate oral cancer vaccine (Q93062126) (← links)